Discuva, Roche deal

Roche and Discuva partnered to discover and develop antibiotics using the biotech's selective antibiotic target identification (SATIN) technology to treat infections caused by multi-drug-resistant (MDR), Gram-negative bacteria. Discuva will receive $16 million up front and is eligible for research fees and up to $175 million in milestones per product, plus up to double-digit royalties. Roche said the partners will jointly conduct lead identification and optimization. The pharma will be responsible for preclinical and clinical development. ...